Date:4/7/2011

but some last as long as three days.  On average, migraine sufferers experience 3 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly.  The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX, an orally inhaled investigational therapy for the acute treatment of migraine. The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.  Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the preparation and filing of a New Drug Application and the regulatory process to have the company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking stat
'/>"/>

SOURCE MAP Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
2. MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression